



Correction to Endorsements in: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

We regret that the articles contained within the recent supplement issue of *CHEST* (February 2012; 141[2][Suppl]:1S-e801S) incorrectly listed the name of one of the endorsing societies in the "Acknowledgments" section. The organization listed on publication as "the International Society of Thrombosis and Hemostasis" should be shown as "the International Society on Thrombosis and Haemostasis." We apologize for any confusion.

Correction to Dosage in: Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

We regret that the article "Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" published in the February 2012 supplement of *CHEST* (2012;141[2][Suppl]:7S-47S) contained an error in a dosage. The related suggestion appears on p. 35S within the second bullet under the section numbered 3.2.1-3.2.5. The original text was missing the word "twice." The corrected text reads:

- We suggest ticagrelor 90 mg twice daily plus low dose aspirin over clopidogrel 75 mg daily plus low-dose aspirin (Grade 2B).

This error also appeared twice within the article "Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" (2012;141[2][Suppl]:e637S-e668S) published in the same supplement. Both online articles have been corrected.

Correction to Dosages, References, and Wording in: Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

We regret that the article "Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention

of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" published in the February 2012 supplement of *CHEST* (2012;141[2][Suppl]:e326S-e350S) contained several errors that have since been corrected in the online article.

On page e329S under the bullet "Bridging dose regimens," the statements in bullet numbers two and three included references to kilograms in error. The statements should read:

2. A low-dose (prophylactic-dose) heparin regimen involves administering a dose that is used, typically, to prevent post-operative VTE (eg, enoxaparin 30 mg bid or 40 mg daily, dalteparin 5,000 International Units daily, UFH 5,000-7,500 International Units bid).
3. An intermediate-dose regimen has recently been studied for bridging and is intermediate in anticoagulant intensity between high- and low-dose regimens (eg, enoxaparin 40 mg bid).

On page e340S in section 3.6 in the upper half of the right column, some of the phrasing and references has been corrected. The changes now reflected in the online article are shown in bold as follows: "... or need for blood transfusion.¹⁷⁵ **Other observational studies** have also found a reduction in cardiovascular events and overall mortality in patients who continue ASA prior to CABG surgery¹⁷⁶ **or start ASA after surgery.**⁴³

Finally, on page e349S, references 175 and 176 were incorrectly ordered. In the corrected file online, the original reference 175 is now 176 and vice versa.

Correction to Dosage in: Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

We regret that the article "Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" published in the February 2012 supplement of *CHEST* (2012;141[2][Suppl]:e637S-e668S) contained an error in a dosage. The related suggestion appears twice within the article (p. e638S and e655S) within the second bullet under the section numbered 3.2.1-3.2.5. The original text was missing the word "twice." The corrected text reads:

- We suggest ticagrelor 90 mg twice daily plus low dose aspirin over clopidogrel 75 mg daily plus low-dose aspirin (Grade 2B).

This error also appeared within the "Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" (2012;141[2][Suppl]:7S-47S) published in the same supplement. Both online articles have been corrected.